The drawn-out process for diagnosing Lyme disease could become a thing of the past – good news for the thousands of people each year who get the tick-borne illness.
A new detection test created by Ionica Sciences – located at Cornell’s McGovern Center life sciences incubator – has been sparked by a FuzeHub grant to begin moving from the laboratory bench into approvals, production and doctors’ offices.
“For a long time, the medical community has wanted to detect Lyme disease directly, but the marker proteins are at very low levels and medicine has relied on tests of the body’s immune response – which sometimes takes weeks,” said Joel Tabb, president and co-founder of Ionica Sciences. “We have resolved this problem and can directly detect those markers in a very small blood sample. It’s a major breakthrough.”
Ionica Sciences, which joined the McGovern Center in 2014, has developed a serum-based assay called IonLyme that targets the blood protein Osp-A, which provides an active-protein “fingerprint” left behind by the bacteria that causes Lyme disease.
Read more at Cornell University
Photo: Sarah Poole and Joel Tabb of Ionica Sciences watch as samples are distributed onto a proprietary Lyme disease assay plate using an automated liquid handling system. CREDIT: Lindsay France/Cornell University